Company intelligence / Profile preview
Cornerstone Pharmaceuticals
- Ownership
- Private
- Development stage
- Other
Overview
Cornerstone’s lead compound CPI‑613® (devimistat) disrupts mitochondrial energy production in tumor cells. It has shown promising results in early clinical trials for hard-to-treat cancers such as AML, pancreatic, biliary tract cancers, and others. The company focuses on rare cancers with significant unmet needs and continues to advance its pipeline through clinical development with multiple orphan drug designations from the FDA and EMA.[3][4]
- Therapeutic areas
- OncologyHematology
- Modalities
- Small molecules (notably lipoic acid derivatives)[5]Anti-metabolic agents targeting cancer cell metabolism[1][5]
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Cornerstone Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cornerstone Pharmaceuticals.